nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.10.2004 | Original Article

^99mTc-depreotide scintigraphy of bone lesions in patients with lung cancer

verfasst von: Esther Mena, Valle Camacho, Montserrat Estorch, Jordi Fuertes, Albert Flotats, Ignasi Carrió

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 10/2004

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Scintigraphy with ^99mTc-depreotide, a somatostatin analogue–technetium ligand, has been used for evaluation of various malignant neoplasms, including lung cancer. The diagnosis of bone metastases in patients with lung cancer is not always definitive with current imaging methods. Visualisation of somatostatin receptors (SSTRs) in bone lesions, when the primary tumour exhibits such receptors, could be helpful in characterising them as metastatic. The aim of this study was to assess the value of ^99mTc-depreotide in differentiating between benign and malignant bone lesions in patients with lung cancer.

Methods

The study population comprised 20 patients (17 males and three females, mean age 63 years) with proven lung cancer in whom bone lesions had been detected by conventional imaging methods. All patients underwent ^99mTc-hydroxydiethylene diphosphonate and ^99mTc-depreotide scintigraphy within 2 weeks. Bone lesions were classified as benign or malignant on the basis of clinical, imaging and/or histological criteria.

Results

^99mTc-depreotide uptake in the primary tumour was seen in 19 of the 20 patients. Conventional imaging methods detected 55 bone lesions, 31 of which were classified as malignant. Twenty-eight (90%) of these lesions showed ^99mTc-depreotide uptake, suggesting bone metastases, while three did not. Twenty-four bone lesions were classified as benign by conventional imaging methods, and none of them showed ^99mTc-depreotide uptake. In addition, ^99mTc-depreotide demonstrated extra-osseous lesions in six patients.

Conclusion

In patients with lung cancer and bone lesions, ^99mTc-depreotide scintigraphy uptake in the bone lesions supports the diagnosis of malignancy, in particular if the primary lung tumour also exhibits SSTRs. Furthermore, whole-body ^99mTc-depreotide scintigraphy may disclose extra-osseous disease.

Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest 2003;123:21S–49SPubMed

Janssen-Heijnen ML, Coebergh JW. The changing epidemiology of lung cancer in Europe. Lung Cancer 2003;41:245–58CrossRefPubMed

Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23–47PubMed

Bach PB, Niewoehner DE, Black WC. Screening for lung cancer: the guidelines. Chest 2003;123:83S–8SCrossRefPubMed

Tan BB, Flaherty KR, Kazerooni EA, Iannettoni MD, American College of Chest Physicians. The solitary pulmonary nodule. Chest 2003;123:89S–96SCrossRefPubMed

Valkema R, Steens J, Cleton FJ, Pauwels EK. The diagnostic utility of somatostatin receptor scintigraphy in oncology. J Cancer Res Clin Oncol 1996;122:513–32PubMed

O’Byrne KJ, Carney DN. Radiolabeled somatostatine analogue scintigraphy in oncology. Anticancer Drugs 1996;7:33–4

Kwekkeboom DJ, Kho GS, Lamberts SW, Reubi JC, Laissue JA, Krenning EP. The value of octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med 1994;221:1106–13

Virgolini I, Traub T, Novotny C, Leimer M, Fuger B, Li SR, Patri P, Paugerf T, Angelberger P, Raderer M, Andreae F, Kurtaran A, Dudczak R. New trends in peptide receptor radioligands. Q J Nucl Med 2001;45:153–9PubMed

10.

Blum J, Handmaker H, Lister-James J, Rinne N. A multicenter trial with a somatostatin analog ^99mTc depreotide in the evaluation of solitary pulmonary nodules. Chest 2000;117:1232–8PubMed

11.

Vallabhajosula S, Moyer BR, Lister-James J, McBride BJ, Lipszyc H, Lee H, Bastidas D, Dean RT. Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides. J Nucl Med 1996;37:1016–22PubMed

12.

Grewal RK, Dadparvar S, Yu JQ, Babaria CJ, Cavanaugh T, Sherman M, Jacobstein J. Efficacy of Tc-99m depreotide scintigraphy in the evaluation of solitary pulmonary nodules. Cancer J 2002;8:400–4PubMed

13.

Blum J, Handmaker H, Rinne NA. Technetium labeled small peptide radiopharmaceuticals in the identification of lung cancer. Curr Pharm Des 2002;8:1827–36PubMed

14.

Morehead RS, Shih WJ. Tc-99m-labeled somatostatin receptor-binding peptide imaging for a pulmonary nodule. Clin Nucl Med 2001;26:910–2CrossRefPubMed

15.

Reubi JC, Schaer JC, Markwalder R, Waser B, Horisberger U, Laissue J. Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potencial relevance. Yale J Biol Med 1997;70:471–9

16.

Kwekkeboom DJ, Krenning EP, Bakker WH, Oei HY, Kooij PP, Lamberts SW. Somatostatin analogue scintigraphy in carcinoid tumours. Eur J Nucl Med 1993;20:283–92PubMed

17.

Leitha T, Meghdadi S, Studnicka M, Wolzt M, Marosi C, Angelberger P, Neumann M, Schlick W, Kletter K, Dudczak R. The role of iodine-123-Tyr-3-octreotide scintigraphy in the staging of small-cell lung cancer. J Nucl Med 1993;34:1397–402PubMed

18.

Breeman WA, De Jong M, Kwekkeboom DJ, Valkema R, Bakker WH, Kooij PP, Visser YJ, Krenning EP. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001;28:1421–9PubMed

19.

Traub T, Petkov V, Ofluoglu S, Pangerl T, Raderer M, Fueger BJ, Schima W, Kurtaran A, Dudczak R, Virgolini I. ¹¹¹In-DOTA-lanreotide scintigraphy in patient with tumors of the lung. J Nucl Med 2001;42:1309–15PubMed

20.

Menda Y, Kahn D. Somatostatin receptor imaging of non-small cell lung cancer with ^99mTc depreotide. Semin Nucl Med 2002;32:92–6CrossRefPubMed

21.

Reisinger I, Bohuslavitzki KH, Brenner W, Braune S, Dittrich I, Geide A, Kettner B, Otto HJ, Schmidt S, Munz DL. Somatostatin receptor scintigraphy in small-cell lung cancer: results of a multicenter study. J Nucl Med 1998;39:224–7PubMed

22.

Stokkel MP, Kwa BM, Pauwels EK. Imaging and staging of small-cell lung cancer: is there a future role for octreotide scintigraphy? Br J Clin Pract 1995;49:235–8PubMed

23.

Fujita T, Yamaji Y, Sato M, Murao K, Takahara J. Gene expression of somatostatin receptor subtypes, SSTR1 and SSTR2 in human lung cancer lines. Life Sci 1994;55:1797–806CrossRefPubMed

24.

Virgolini I, Leimer M, Handmaker H, Lastoria S, Bischof C, Muto P, Pangerl T, Gludovacz D, Peck-Radosavljevic M, Lister-James J, Hamilton G, Kaserer K, Valent P, Dean R. Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, ^99mTc-P829. Cancer Res 1998;58:1850–9PubMed

25.

Kagohashi K, Satoh H, Ishikawa H, Ohtsuka M, Sekizawa K. Bone metastasis as the first manifestation of lung cancer. Int J Clin Pract 2003;57:184–6PubMed

26.

Scutellari PN, Antinolfi G, Galeotti R, Giganti M. Metastatic bone disease. Strategies for imaging. Minerva Med 2003;94:77–90PubMed

27.

Nakamoto Y, Osman M, Wahl RL. Prevalence and patterns of bone metastases detected with positron emission tomography using F-18 FDG. Clin Nucl Med 2003;28:302–7CrossRefPubMed

28.

Kahn D, Menda Y, Kernstine K, Bushnell D, Mclaughlin K, Miller S, Berbaum K. The utility of ^99mTc-depreotide compared with F-18 fluorodeoxyglucose positron emission tomography and surgical staging in patients with suspected non-small cell lung cancer. Chest 2004;125:494–501CrossRefPubMed

29.

Zuetenhorst JM, Hoefnagel CA, Boot H, Valdés-Olmos RA, Taal BG. Evaluation of ¹¹¹In-pentetreotide, ¹³¹I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl Med Commun 2002;23:735–41CrossRefPubMed

30.

Lebtahi R, Cadiot G, Delahaye N, Genin R, Daou D, Peker MC, Chosidow D, Faraggi M, Mignon M, Le Guludec D. Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy. J Nucl Med 1999;40:1602–8PubMed

31.

Gibril F, Doppman JL, Reynolds JC, Chen CC, Sutliff VE, Yu F, Serrano J, Venzon DJ, Jensen RT. Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location and effect of their detection on management. J Clin Oncol 1998;16:1040–53

32.

Steger W, Amthauer H, Vogl TJ, Wiedenmann B, Steger S, Eichstadt H. Detection of bone metastases in patients with neuroendocrine gastrointestinal tumors. Radiologe 1999;39:235–40CrossRefPubMed

33.

Van de Wiele C, Signore A, Dierckx RA. Peptide receptor imaging: advances in the diagnosis of pulmonary diseases. Am J Respir Med 2002;1:177–83PubMed

34.

Vanhagen PM, krenninf EP, Reubi JC, Kwekkeboom DJ, Bakker WH, Mulder AH, Laissure I, Hoogstede HC, Lamberts SW. Somatostatin analogue scintigraphy in granulomatous diseases. Eur J Nucl Med 1994;21:497–502PubMed

35.

Sreedharan SP, Kodama KT, Peterson KE, Goetzl EJ. Distinct subsets of somatostatin receptors on cultured human lymphocytes. J Biol Chem 1989;264:497–502

36.

Krenning EP, Kwekkeboom DJ, Bakker W. Somatostatin receptor scintigraphy with In-111-DTPA-d-Phe1 and I-131-Try-3-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716–31PubMed

37.

Machac J, Krynyckyi B, Kim C. Peptide and antibody imaging in lung cancer. Semin Nucl Med 2002;32:276–92CrossRefPubMed

Titel: 99mTc-depreotide scintigraphy of bone lesions in patients with lung cancer
verfasst von: Esther Mena
Valle Camacho
Montserrat Estorch
Jordi Fuertes
Albert Flotats
Ignasi Carrió
Publikationsdatum: 01.10.2004
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 10/2004
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-004-1594-x

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2004

Value of 18F-FDG PET in the detection of peritoneal carcinomatosis

Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours

Whole-body muscle gallium uptake in a large B-cell non-Hodgkin lymphoma

The growing importance of continuing medical education in nuclear medicine: the role of the European School of Nuclear Medicine

Yearbook of nuclear medicine 2003

Incidence of radiation-induced Graves’ disease in patients treated with radioiodine for thyroid autonomy before and after introduction of a high-sensitivity TSH receptor antibody assay